# US 2017/0283509 A1 · Blocking monoclonal antibodies to agr2 and its receptor c4.4a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283509 A1
- Document ID: US20170283509A1
- Status: Published application
- Kind: A1
- Application number: 15/509,790
- Filed: 2015-09-08
- Published: 2017-10-05
- Earliest claimed: 2014-09-09
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Craig D. LOGSDSON; Vijaya RAMACHANDRAN; Thiruvengadam ARUMUGAM
- Web page: https://patentgrep.com/patent/US20170283509A1

## CPC

- C07K 16/40: against enzymes
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C07K 16/303: {Liver or Pancreas}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Also provided herein are methods of using said antibodies to treat cancer.

## Claims

### Claim at position 1

1-81. (canceled)

### Claim 82

An isolated monoclonal antibody, wherein the antibody specifically binds to a AGR2 polypeptide and wherein the antibody competes for binding of the polypeptide with a 163-28B-1 monoclonal antibody.

### Claim 83 (depends on 82)

The antibody of claim 82, wherein the antibody comprises:
(a) a first VH CDR at least 90% identical to VH CDR1 of 163-28B-1 (SEQ ID NO: 20);
(b) a second VH CDR at least 90% identical to VH CDR2 of 163-28B-1 (SEQ ID NO: 21);
(c) a third VH CDR at least 90% identical to VH CDR3 of 163-28B-1 (SEQ ID NO: 22);
(d) a first VL CDR at least 90% identical to VL CDR1 of 163-28B-1 (SEQ ID NO: 23);
(e) a second VL CDR at least 90% identical to VL CDR2 of 163-28B-1 (SEQ ID NO: 24); and
(f) a third VL CDR at least 90% identical to VL CDR3 of 163-28B-1 (SEQ ID NO: 25).

### Claim 84 (depends on 83)

The isolated antibody of claim 83, wherein the antibody comprises:
(a) a first VH CDR is identical to SEQ ID NO: 20;
(b) a second VH CDR is identical to SEQ ID NO: 21;
(c) a third VH CDR is identical to SEQ ID NO: 22;
(d) a first VL CDR is identical to SEQ ID NO: 23;
(e) a second VL CDR is identical to SEQ ID NO: 24; and
(f) a third VL CDR is identical to SEQ ID NO: 25.

### Claim 85 (depends on 82)

The isolated antibody of claim 82, wherein the antibody comprises:
(a) a first VH CDR at least 90% identical to SEQ ID NO: 20;
(b) a second VH CDR at least 90% identical to SEQ ID NO: 21;
(c) a third VH CDR at least 90% identical to SEQ ID NO: 22; and
(d) a VL domain at least 90% identical to SEQ ID NO: 19.

### Claim 86 (depends on 85)

The isolated antibody of claim 85, wherein the antibody comprises:
(a) a first VH CDR identical to SEQ ID NO: 20;
(b) a second VH CDR identical to SEQ ID NO: 21;
(c) a third VH CDR identical to SEQ ID NO: 22; and
(d) a VL domain identical to SEQ ID NO: 19.

### Claim 87 (depends on 82)

The isolated antibody of claim 82, wherein the antibody comprises:
(a) a VH domain at least 90% identical to SEQ ID NO: 18;
(b) a first VL CDR at least 90% identical to SEQ ID NO: 23;
(c) a second VL CDR at least 90% identical to SEQ ID NO: 24; and
(d) a third VL CDR at least 90% identical to SEQ ID NO: 25.

### Claim 88 (depends on 87)

The isolated antibody of claim 87, wherein the antibody comprises:
(a) a VH domain identical to SEQ ID NO: 18;
(b) a first VL CDR identical to SEQ ID NO: 23;
(c) a second VL CDR identical to SEQ ID NO: 24; and
(d) a third VL CDR identical to SEQ ID NO: 25.

### Claim 89 (depends on 83)

The isolated antibody of claim 83, wherein the antibody comprises a VH domain at least about 80% identical to the VH domain of 163-28B-1 (SEQ ID NO: 18) and a VL domain at least about 80% identical to the VL domain of 163-28B-1 (SEQ ID NO: 19).

### Claim 90 (depends on 89)

The isolated antibody of claim 89, wherein the antibody comprises a VH domain identical to the VH domain of 163-28B-1 (SEQ ID NO: 18) and a VL domain identical to the VL domain of 163-28B-1 (SEQ ID NO: 19).

### Claim 91 (depends on 90)

The isolated antibody of claim 90, wherein the antibody is the 163-28B-1 antibody.

### Claim 92

A monoclonal antibody, or an antigen binding fragment thereof, specific to the AGR2 polypeptide wherein the antibody binds specifically to the AGR2 epitope NH2-IHHLDECPHSQALKKVFAENKEIQKLAEQ-C (SEQ ID NO: 28).

### Claim 93 (depends on 92)

The monoclonal antibody, or an antigen binding fragment thereof, of claim 92, wherein the monoclonal antibody, or an antigen binding fragment thereof, inhibits tumor cell pancreatic ductal adenocarcinoma migration and resistance to gemcitabine-induced apoptosis.

### Claim 94 (depends on 82)

The isolated antibody of claim 82, wherein the antibody is recombinant.

### Claim 95 (depends on 82)

The isolated antibody of claim 82, wherein the antibody is an IgG, IgM, IgA or an antigen binding fragment thereof.

### Claim 96 (depends on 82)

The isolated antibody of claim 82, wherein the antibody is a Fab′, a F(ab′)2, a F(ab′)3, a monovalent scFv, a bivalent scFv, or a single domain antibody.

### Claim 97 (depends on 82)

The isolated antibody of claim 82, wherein the antibody is a human, humanized antibody or de-immunized antibody.

### Claim 98 (depends on 82)

The isolated antibody of claim 82, wherein the antibody is conjugated to an imaging agent, a chemotherapeutic agent, a toxin or a radionuclide.

### Claim 99

An isolated monoclonal antibody, wherein the antibody specifically binds to a C4.4A polypeptide and wherein the antibody competes for binding of the polypeptide with a 162-1A-1 monoclonal antibody.

### Claim 100 (depends on 99)

The antibody of claim 99, wherein the antibody comprises:
(a) a first VH CDR at least 90% identical to VH CDR1 of 162-1A-1 (SEQ ID NO: 12);
(b) a second VH CDR at least 90% identical to VH CDR2 of 162-1A-1 (SEQ ID NO: 13);
(c) a third VH CDR at least 90% identical to VH CDR3 of 162-1A-1 (SEQ ID NO: 14);
(d) a first VL CDR at least 90% identical to VL CDR1 of 162-1A-1 (SEQ ID NO: 15);
(e) a second VL CDR at least 90% identical to VL CDR2 of 162-1A-1 (SEQ ID NO: 16); and
(f) a third VL CDR at least 90% identical to VL CDR3 of 162-1A-1 (SEQ ID NO: 17).

### Claim 101 (depends on 100)

The isolated antibody of claim 100, wherein the antibody comprises:
(a) a first VH CDR is identical to SEQ ID NO: 12;
(b) a second VH CDR is identical to SEQ ID NO: 13;
(c) a third VH CDR is identical to SEQ ID NO: 14
(d) a first VL CDR is identical to SEQ ID NO: 15;
(e) a second VL CDR is identical to SEQ ID NO: 16; and
(f) a third VL CDR is identical to SEQ ID NO: 17.

### Claim 102 (depends on 99)

The isolated antibody of claim 99, wherein the antibody comprises:
(a) a first VH CDR at least 90% identical to SEQ ID NO: 12;
(b) a second VH CDR at least 90% identical to SEQ ID NO: 13;
(c) a third VH CDR at least 90% identical to SEQ ID NO: 14; and
(d) a VL domain at least 90% identical to SEQ ID NO: 11.

### Claim 103 (depends on 102)

The isolated antibody of claim 102, wherein the antibody comprises:
(a) a first VH CDR identical to SEQ ID NO: 12;
(b) a second VH CDR identical to SEQ ID NO: 13;
(c) a third VH CDR identical to SEQ ID NO: 14; and
(d) a VL domain identical to SEQ ID NO: 11.

### Claim 104 (depends on 99)

The isolated antibody of claim 99, wherein the antibody comprises:
(a) a VH domain at least 90% identical to SEQ ID NO: 10;
(b) a first VL CDR at least 90% identical to SEQ ID NO: 15;
(c) a second VL CDR at least 90% identical to SEQ ID NO: 16; and
(d) a third VL CDR at least 90% identical to SEQ ID NO: 17.

### Claim 105 (depends on 104)

The isolated antibody of claim 104, wherein the antibody comprises:
(a) a VH domain identical to SEQ ID NO: 10;
(b) a first VL CDR identical to SEQ ID NO: 15;
(c) a second VL CDR identical to SEQ ID NO: 16; and
(d) a third VL CDR identical to SEQ ID NO: 17.

### Claim 106 (depends on 100)

The isolated antibody of claim 100, wherein the antibody comprises a VH domain at least about 80% identical to the VH domain of 162-1A-1 (SEQ ID NO: 10) and a VL domain at least about 80% identical to the VL domain of 162-1A-1 (SEQ ID NO: 11).

### Claim 107 (depends on 106)

The isolated antibody of claim 106, wherein the antibody comprises a VH domain identical to the VH domain of 162-1A-1 (SEQ ID NO: 10) and a VL domain identical to the VL domain of 162-1A-1 (SEQ ID NO: 11).

### Claim 108 (depends on 107)

The isolated antibody of claim 107, wherein the antibody is the 163-28B-1 antibody.

### Claim 109

A monoclonal antibody, or an antigen binding fragment thereof, specific to the C4.4A polypeptide wherein the antibody binds specifically to the C4.4A epitope NH2-PVRPTSTTKPMPAPTSQTPRQGVEHEASRDEEPRL-C (SEQ ID NO: 29).

### Claim 110 (depends on 109)

The monoclonal antibody, or an antigen binding fragment thereof, of claim 109, wherein the monoclonal antibody, or an antigen binding fragment thereof, inhibits tumor cell pancreatic ductal adenocarcinoma migration and resistance to gemcitabine-induced apoptosis.

### Claim 111 (depends on 99)

The isolated antibody of claim 99, wherein the antibody is recombinant.

### Claim 112 (depends on 99)

The isolated antibody of claim 99, wherein the antibody is an IgG, IgM, IgA or an antigen binding fragment thereof.

### Claim 113 (depends on 99)

The isolated antibody of claim 99, wherein the antibody is a Fab′, a F(ab′)2, a F(ab′)3, a monovalent scFv, a bivalent scFv, or a single domain antibody.

### Claim 114 (depends on 99)

The isolated antibody of claim 99, wherein the antibody is a human, humanized antibody or de-immunized antibody.

### Claim 115 (depends on 99)

The isolated antibody of claim 99, wherein the antibody is conjugated to an imaging agent, a chemotherapeutic agent, a toxin or a radionuclide.

### Claim 116 (depends on 82)

A composition comprising an antibody of claim 82 in a pharmaceutically acceptable carrier.

### Claim 117 (depends on 99)

A composition comprising an antibody of claim 99 in a pharmaceutically acceptable carrier.

### Claim 118

A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of 163-28B-1 (SEQ ID NOs: 20, 21, and 22).

### Claim 119

A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of 162-1A-1 (SEQ ID NOs: 12, 13, and 14).

### Claim 120

A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 163-28B-1 (SEQ ID NOs: 23, 24, and 25).

### Claim 121

A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 162-1A-1 (SEQ ID NOs: 15, 16, and 17).

### Claim 122 (depends on 82)

A method of manufacturing an antibody comprising:
(a) expressing one or more polynucleotide molecule(s) encoding a VL and VH chain of an antibody of claim 82; and
(b) purifying the antibody from the cell.

### Claim 123

A method for treating cancer in a patient comprising administering to the patient an agent that disrupts the AGR2/C4.4A interaction in an amount effective to treat the cancer.

### Claim 124

A method for treating a subject having a cancer comprising administering an effective amount of a monoclonal antibody, or antigen binding fragment thereof, which binds specifically to the AGR2 epitope NH2-IHHLDECPHSQALKKVFAENKEIQKLAEQ-C (SEQ ID NO: 28).

### Claim 125

A method for treating a subject having a cancer comprising administering an effective amount of a monoclonal antibody, or antigen binding fragment thereof, which binds specifically to the C4.4A epitope NH2-PVRPTSTTKPMPAPTSQTPRQGVEHEASRDEEPRL-C (SEQ ID NO: 29).

### Claim 126 (depends on 82)

A method for treating a subject having a cancer comprising administering an effective amount of an antibody of claim 82 to the subject.

### Claim 127 (depends on 126)

The method of claim 126, wherein the cancer is a breast cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, skin cancer brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer.

### Claim 128 (depends on 126)

The method of claim 126, wherein the cancer is a pancreatic ductal adenocarcinoma.

### Claim 129 (depends on 126)

The method of claim 126, wherein the antibody is administered systemically.

### Claim 130 (depends on 126)

The method of claim 126, wherein the antibody is administered intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, or locally.

### Claim 131 (depends on 126)

The method of claim 126, further comprising administering at least a second anticancer therapy to the subject.

### Claim 132 (depends on 131)

The method of claim 131, wherein the second anticancer therapy is a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, immunotherapy or cytokine therapy.

### Claim 133 (depends on 126)

The method of claim 126, wherein the subject is a human subject.
